Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741827 | 1.00 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL2045566 | 0.85 | GRIN2D (0.31) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL2045564 | 0.85 | GRIN2D (0.31) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6194463 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL1857397 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6194459 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL11063309 | 0.84 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| Iodide SCHEMBL7250541 | 0.84 | — | — | |
| Iodide SCHEMBL7254660 | 0.84 | — | — | |
| SCHEMBL7247702 | 0.83 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027073-A2 | ENHANCED EFFECTS FOR HAPTEN CONJUGATED THERAPEUTICS | SANGSTAT MEDICAL CORPORATION (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998022141-A2 | ENHANCED EFFECTS FOR HAPTEN CONJUGATED THERAPEUTICS | SANGSTAT MEDICAL CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |